Small RNA Sequencing Identifies PIWI-Interacting RNAs Deregulated in Glioblastoma-piR-9491 and piR-12488 Reduce Tumor Cell Colonies
PIWI-interacting RNA
diagnosis
glioblastoma
piRNA
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
05
2021
accepted:
20
07
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
7
9
2021
Statut:
epublish
Résumé
Glioblastoma (GBM) is the most frequently occurring primary malignant brain tumor of astrocytic origin. To change poor prognosis, it is necessary to deeply understand the molecular mechanisms of gliomagenesis and identify new potential biomarkers and therapeutic targets. PIWI-interacting RNAs (piRNAs) help in maintaining genome stability, and their deregulation has already been observed in many tumors. Recent studies suggest that these molecules could also play an important role in the glioma biology. To determine GBM-associated piRNAs, we performed small RNA sequencing analysis in the discovery set of 19 GBM and 11 non-tumor brain samples followed by TaqMan qRT-PCR analyses in the independent set of 77 GBM and 23 non-tumor patients. Obtained data were subsequently bioinformatically analyzed. Small RNA sequencing revealed 58 significantly deregulated piRNA molecules in GBM samples in comparison with non-tumor brain tissues. Deregulation of piR-1849, piR-9491, piR-12487, and piR-12488 was successfully confirmed in the independent groups of patients and controls (all
Identifiants
pubmed: 34485142
doi: 10.3389/fonc.2021.707017
pmc: PMC8415021
doi:
Types de publication
Journal Article
Langues
eng
Pagination
707017Informations de copyright
Copyright © 2021 Bartos, Siegl, Kopkova, Radova, Oppelt, Vecera, Kazda, Jancalek, Hendrych, Hermanova, Kasparova, Pleskacova, Vybihal, Fadrus, Smrcka, Lakomy, Lipina, Cesak, Slaby and Sana.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Mol Sci. 2020 Jul 13;21(14):
pubmed: 32668808
Theranostics. 2018 Jan 1;8(4):1084-1105
pubmed: 29464001
Oncotarget. 2014 Oct 30;5(20):9901-10
pubmed: 25313140
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
Annu Rev Biochem. 2015;84:405-33
pubmed: 25747396
Clin Transl Oncol. 2013 Jul;15(7):563-8
pubmed: 23229900
N Engl J Med. 2008 Jul 31;359(5):492-507
pubmed: 18669428
Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):160-169
pubmed: 30599187
Asia Pac J Clin Oncol. 2018 Feb;14(1):40-51
pubmed: 28840962
Mol Ther Nucleic Acids. 2018 Mar 2;10:412-425
pubmed: 29499952
J Exp Clin Cancer Res. 2018 Oct 11;37(1):246
pubmed: 30305135
Cancer Lett. 2012 Feb 1;315(1):12-7
pubmed: 22047710
Cell Physiol Biochem. 2017;44(1):1-20
pubmed: 29130960
Sci Rep. 2018 Feb 12;8(1):2836
pubmed: 29434344
Nat Commun. 2015 Jun 22;6:7316
pubmed: 26095918
Commun Biol. 2018 Jan 22;1:2
pubmed: 30271890
Clin Cancer Res. 2013 Feb 15;19(4):764-72
pubmed: 23209033
Oncotarget. 2018 Dec 28;9(102):37616-37626
pubmed: 30701019
Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150
pubmed: 28815663
J Hematol Oncol. 2015 Apr 21;8:38
pubmed: 25895683
Leukemia. 2015 Jan;29(1):196-206
pubmed: 24732595
Cancer Lett. 2015 Jan 28;356(2 Pt B):561-7
pubmed: 25305452
Epigenomics. 2015;7(6):975-84
pubmed: 25929784
J Clin Oncol. 2017 Jul 20;35(21):2402-2409
pubmed: 28640706
Nature. 2014 Jan 16;505(7483):353-359
pubmed: 24429634
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082